RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions.
Qure.Ai Technologies Inc.
Qure.ai is a health tech company that uses deep learning and Artificial Intelligence (AI) to make healthcare more accessible and equitable for patients worldwide. Our solutions power the efficient identification and management of Tuberculosis (TB), Lung Cancer and Stroke to support clinicians and propel developments in the pharmaceutical and medical device industries. We empower healthcare by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life. | About Qure.ai Qure.ai is a global health tech company that innovates AI-enabled healthcare solutions to drive early clinical diagnosis and boost seamless patient care coordination. Qure’s solutions power the efficient identification and management of TB, Lung Cancer and Neurocritical findings to support clinicians and propel developments in the pharmaceutical and medical device industries. The company empowers healthcare workers or health systems by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life. Qure.ai has deployments in over 100 countries, with regional offices in New York, London, Dubai and Mumbai. It is a TIME100 Most Influential Company 2025.
QMENTA
QMENTA provides AI-powered imaging infrastructure designed for radiology and clinical research. Our cloud-native platform centralizes image data, automates quality control, and supports advanced review workflows across multi-site studies. From data ingestion to central read and adjudication, QMENTA helps imaging teams ensure compliance, maintain data integrity, and accelerate study timelines.
PurpleAI
PurpleAI is a fast-growing medical AI pioneer transforming stroke care through intelligent automation—enhancing workflow efficiency and diagnostic accuracy to drive better patient outcomes. Building on the proven success of its diagnostic support AI solutions, PurpleAI is now expanding into multi-modal, predictive analytics. Its upcoming flagship SaMD, StrokeShieldAI, is designed to anticipate and monitor high-risk complications following initial stroke treatment. By equipping clinicians with real-time foresight, StrokeShieldAI enables earlier intervention, mitigates adverse outcomes, and sets a new standard for stroke care. | Founded as an independent company in October 2024 (after operating within SK Group since 2019), PurpleAI is a fast-growing medical AI innovator transforming stroke care through intelligent automation and predictive insight—enhancing workflow efficiency, diagnostic accuracy, and patient outcomes. PurpleAI is expanding its Hyper Insight™ portfolio across multiple imaging modalities and advancing into multi-modal, data-driven predictive analytics. Its upcoming flagship, StrokeShieldAI, is built to anticipate and monitor high-risk complications after initial stroke treatment—providing clinicians with real-time foresight for earlier intervention and better outcomes.
Promedius
“Healthy Aging through AI” PROMEDIUS pioneers the most advanced breakthroughs with AI in age-related conditions, including osteoporosis. Osteo Signal is the world’s first screening solution that utilizes chest X-ray images to identify patients who may be at risk of osteoporosis. This technology aims to proactively tackle the challenges of osteoporosis by enabling timely identification of potential patients at risk.
Planmed Inc
he Finnish Planmed Oy dedicates its effort to the development, manufacturing and marketing of advanced imaging equipment and accessories that provide a unique combination of image quality and ease of use for medical imaging professionals. The company offers products for mammography and orthopedic imaging that are well-known for imaging performance, user-friendliness and good ergonomics. Since 1987, Planmed systems have provided tools for healthcare professionals in over 80 countries worldwide. The company is part of Finnish Planmeca Group, a well-known company in medical and dental field. | Planmed Oy develops, manufactures and markets advanced imaging equipment and accessories for mammography and orthopedic imaging. Planmed’s extensive mammography product range covers digital and analog mammography units and digital breast tomosynthesis (DBT) systems, stereotactic biopsy devices, and breast positioning systems for an early detection of breast cancer. Within orthopedic 3D imaging Planmed offers low dose Cone Beam CT imaging for quicker, easier and more accurate diagnosis at the point-of-care. Strongly committed to R&D and design, Planmed Oy exports more than 98% of its production to over 70 countries worldwide. Planmed Oy, headquartered in Helsinki, Finland, was established in 1989. Planmed Oy is part of the Finland-based Planmeca Group that manufactures and markets state-of-the-art products for medical and dental fields.
PanCAD.ai
【PANCREASaver™ : A Novel Computer-Assisted Detection (CAD) Tool for Early Pancreatic Cancer (PC)】 Computed tomography (CT) is the major modality for detecting PC, but small PCs are often obscure, with approximately 40% of tumors less than 2 cm being missed on CT. PANCREASaver is an automatic tool that determines whether CT images harbor PC and indicate tumor location without requiring manual image processing. ✅ FDA Breakthrough Device ✅ Taiwan FDA Approved ✅ US and Taiwan Patented ✅ Validated by Nationwide Real-World Data – Radiology 306(1):172-182, 2023. 2023 RSNA Margulis Award | 【PANCREASaver™ : A Novel Computer-Assisted Detection (CAD) Tool for Early Pancreatic Cancer (PC)】 Computed tomography (CT) is the primary modality for detecting PC, but small PCs are often obscured, with approximately 40% of tumors less than 2 cm missed on CT. PANCREASaver is an automatic tool that determines whether CT images harbor PC and indicates tumor location without requiring manual image processing. ✅ FDA Breakthrough Device ✅ Taiwan FDA Approved ✅ US and Taiwan Patented ✅ Validated by Nationwide Real-World Data – Radiology 306(1):172-182, 2023. 2023 RSNA Margulis Award